中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 5
May  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(5): 1144-1148

Autoimmune-like hepatitis induced by Jiegu Qili tablets： A case report

DOI: 10.12449/JCH260520
  • 1.

    Department of Gastroenterology，The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine，Guiyang 550001，China

  • 2.

    Department of Pathology，The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine，Guiyang 550001，China

  • 3.

    Department of Radiology，The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine，Guiyang 550001，China

Research funding:

Guizhou University of Traditional Chinese Medicine’s “2024 Youth Sail” Plan Project (Guizhongyikehe-QNYFZK［2024］No.16);

The Construction of Key Disciplines in Traditional Chinese Medicine and Ethnic Medicine at the Provincial Level in Guizhou in 2023 (QZYYZDXK（JS）-2023-03)

More Information
  • Corresponding author: ZHOU Yunsong， 371025826@qq.com （ORCID： 0009-0005-0952-8930）
  • Received Date: 2025-09-07
  • Accepted Date: 2025-11-05
  • Published Date: 2026-05-25
    Abstract
  • Drug-induced autoimmune-like hepatitis （DI-ALH） is one of the special phenotypes of drug-induced liver injury， and since it has similar autoimmune characteristics and liver histological manifestations as intrinsic autoimmune hepatitis， differential diagnosis of these two diseases may be difficult in some cases. This article reports a case diagnosed with DI-ALH after long-term follow-up and conducts a literature review to provide a reference for clinicians.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    ANDRADE RJ, AITHAL GP, de BOER YS, et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis(DI-ALH): An expert opinion meeting report[J]. J Hepatol, 2023, 79( 3): 853- 866. DOI: 10.1016/j.jhep.2023.04.033.
    [2]
    YE WY, DING Y, LI M, et al. Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database[J]. PLoS One, 2025, 20( 2): e0317680. DOI: 10.1371/journal.pone.0317680.
    [3]
    Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J]. Chin J Gastroenterol, 2023, 28( 7): 397- 431.

    中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2023, 28( 7): 397- 431.
    [4]
    ZHU XJ, ZHOU L. The retrospective analysis of 159 cases with drug-induced liver injury caused by proprietary Chinese medicines[J]. Anhui Med Pharm J, 2024, 28( 8): 1689- 1693. DOI: 10.3969/j.issn.1009-6469.2024.08.043.

    朱晓静, 周梁. 中成药致药物性肝损伤159例回顾性分析[J]. 安徽医药, 2024, 28( 8): 1689- 1693. DOI: 10.3969/j.issn.1009-6469.2024.08.043.
    [5]
    XU HW, WU HW, XU YQ, et al. Acute liver injury due to Gukang capsules, Jieguqili pills, and ibuprofen and codeine phosphate tablets[J]. Adverse Drug React J, 2020, 22( 5): 323- 325. DOI: 10.3760/cma.j.cn114015-20181206-01210.

    徐慧薇, 吴海雯, 徐迎庆, 等. 骨康胶囊、接骨七厘丸和洛芬待因片致急性肝损伤[J]. 药物不良反应杂志, 2020, 22( 5): 323- 325. DOI: 10.3760/cma.j.cn114015-20181206-01210.
    [6]
    LIU XY. Drug intervention and pharmaceutical care of a patient with drug-induced liver injury caused by combined medication[J]. Diet Health, 2025( 9): 7- 9. DOI: 10.3969/j.issn.2095-8439.2025.09.003.

    刘晓彦. 1例因联合用药导致药物性肝损伤患者的用药干预及药学监护[J]. 饮食保健, 2025( 9): 7- 9. DOI: 10.3969/j.issn.2095-8439.2025.09.003.
    [7]
    BJÖRNSSON HK, BJÖRNSSON ES. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management[J]. Eur J Intern Med, 2022, 97: 26- 31. DOI: 10.1016/j.ejim.2021.10.035.
    [8]
    MURATORI L, LOHSE AW, LENZI M. Diagnosis and management of autoimmune hepatitis[J]. BMJ, 2023, 380: e070201. DOI: 10.1136/bmj-2022-070201.
    [9]
    SUZUKI A, BRUNT EM, KLEINER DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J]. Hepatology, 2011, 54( 3): 931- 939. DOI: 10.1002/hep.24481.
    [10]
    FEBRES-ALDANA CA, ALGHAMDI S, KRISHNAMURTHY K, et al. Liver fibrosis helps to distinguish autoimmune hepatitis from DILI with autoimmune features: A review of twenty cases[J]. J Clin Transl Hepatol, 2019, 7( 1): 21- 26. DOI: 10.14218/JCTH.2018.00053.
    [11]
    ALKASHASH A, ZHANG X, VUPPALANCHI R, et al. Distinction of autoimmune hepatitis from drug-induced autoimmune like hepatitis: The answer lies at the interface[J]. J Hepatol, 2024, 81( 1): e45- e47. DOI: 10.1016/j.jhep.2024.01.023.
    [12]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of autoimmune hepatitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 42- 49.

    中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 42- 49.
    [13]
    CHEN J, WANG C, JIANG W. A case of autoimmune hepatitis complicated with drug-induced liver injury[J]. Chin J Dig, 2023, 43( 4): 274- 276. DOI: 10.3760/cma.j.cn311367-20230201-00035.

    陈洁, 王超, 蒋炜. 自身免疫性肝炎合并药物性肝损伤1例[J]. 中华消化杂志, 2023, 43( 4): 274- 276. DOI: 10.3760/cma.j.cn311367-20230201-00035.
    [14]
    LIU YP, SHEN YJ. Clinical diagnosis of drug-induced autoimmune-like hepatitis[J]. J Clin Hepatol, 2025, 41( 3): 542- 546. DOI: 10.12449/JCH250322.

    刘永萍, 沈瑶杰. 药物诱导的自身免疫样肝炎的临床诊断[J]. 临床肝胆病杂志, 2025, 41( 3): 542- 546. DOI: 10.12449/JCH250322.
    [15]
    EFE C, KULKARNI AV, TERZIROLI BERETTA-PICCOLI B, et al. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome[J]. Hepatology, 2022, 76( 6): 1576- 1586. DOI: 10.1002/hep.32572.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (30) PDF downloads(7) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return